<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Ipsen Sa — News on 6ix</title>
    <link>https://6ix.com/company/ipsen-sa-1</link>
    <description>Latest news and press releases for Ipsen Sa on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 20 May 2026 11:15:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/ipsen-sa-1" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d532debeedb30cb6f6ddbd.webp</url>
      <title>Ipsen Sa</title>
      <link>https://6ix.com/company/ipsen-sa-1</link>
    </image>
    <item>
      <title>National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/national-survey-from-ipsen-shows-young-people-are-not-prepared-for-the-shift-from-pediatric-to-adult-healthcare</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/national-survey-from-ipsen-shows-young-people-are-not-prepared-for-the-shift-from-pediatric-to-adult-healthcare</guid>
      <pubDate>Wed, 20 May 2026 11:15:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., May 20, 2026--Ipsen announces the findings of a new survey showing young people are under-prepared for the move from pediatrics to the adult healthcare system.</description>
    </item>
    <item>
      <title>Ipsen announces late-breaking data from first head-to-head study comparing Dysport and Botox in adults with upper limb spasticity</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-announces-late-breaking-data-from-first-head-to-head-study-comparing-dysport-and-botox-in-adults-with-upper-limb-spasticity</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-announces-late-breaking-data-from-first-head-to-head-study-comparing-dysport-and-botox-in-adults-with-upper-limb-spasticity</guid>
      <pubDate>Wed, 20 May 2026 09:37:38 GMT</pubDate>
      <description>Ipsen announces late-breaking data from first head-to-head study comparing Dysport and Botox in adults with upper limb</description>
    </item>
    <item>
      <title>Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-announces-late-breaking-data-from-first-head-to-head-study-comparing-dysportr-and-botoxr-in-adults-with-upper-limb-spasticity-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-announces-late-breaking-data-from-first-head-to-head-study-comparing-dysportr-and-botoxr-in-adults-with-upper-limb-spasticity-1</guid>
      <pubDate>Tue, 19 May 2026 19:00:00 GMT</pubDate>
      <description>Phase IV head-to-head, double-blind trial comparing safety and efficacy met its primary and secondary endpointsThe DIRECTION trial results show the safety profile for Dysport® (abobotulinumtoxinA) was non-inferior to Botox® (onabotulinumtoxinA) in adult patients with upper limb spasticityPatients treated with Dysport in the DIRECTION trial achieved a longer duration of response than patients treated with BotoxData will be presented at a late-breaking session at the ISPRM congress1 PARIS, FRANCE</description>
    </item>
    <item>
      <title>Ipsen - April 2026- Monthly information relative to the total number of voting rights and shares composing the share capital</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-april-2026-monthly-information-relative-to-the-total-number-of-voting-rights-and-shares-composing-the-share-capital</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-april-2026-monthly-information-relative-to-the-total-number-of-voting-rights-and-shares-composing-the-share-capital</guid>
      <pubDate>Mon, 18 May 2026 16:30:00 GMT</pubDate>
      <description>Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights (1)30 April 202683,814,526Gross total* of voting rights: 131,952,432Net total** of v</description>
    </item>
    <item>
      <title>Ipsen initiates a new share buy-back program</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-initiates-a-new-share-buy-back-program</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-initiates-a-new-share-buy-back-program</guid>
      <pubDate>Mon, 18 May 2026 05:00:00 GMT</pubDate>
      <description>Ipsen initiates a new share buy-back program PARIS, FRANCE, 18 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it has appointed an investment services provider to purchase an aggregate number of up to 350,000 Ipsen S.A. shares, representing approximately 0.42% of the share capital, over a maximum period of six months. The shares purchased under this agreement will be allocated mainly to cover Ipsen’s free employee share-allocation plan and its new employee share-ownership plan.</description>
    </item>
    <item>
      <title>Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-presents-first-in-class-late-breaking-phase-ii-corabotase-data-in-glabellar-lines-showing-sustained-duration-of-effect-reinforced-by-consistently-high-patient-satisfaction</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-presents-first-in-class-late-breaking-phase-ii-corabotase-data-in-glabellar-lines-showing-sustained-duration-of-effect-reinforced-by-consistently-high-patient-satisfaction</guid>
      <pubDate>Sat, 16 May 2026 12:00:00 GMT</pubDate>
      <description>Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration of effect vs placebo and vs Dysport, defined as a score of “none” or “mild” of line severity Patient satisfaction scores at Week 24 were 82.8% Corabotase is currently being evaluated as an investigational treatment in aesthetic indications PARIS, FRANCE, 16 May 2026</description>
    </item>
    <item>
      <title>Annual General Meeting of Ipsen S.A. held on 13 May 2026</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/annual-general-meeting-of-ipsen-sa-held-on-13-may-2026-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/annual-general-meeting-of-ipsen-sa-held-on-13-may-2026-1</guid>
      <pubDate>Wed, 13 May 2026 16:15:00 GMT</pubDate>
      <description>Annual General Meeting of Ipsen S.A. held on 13 May 2026 All the resolutions submitted to the shareholders’ vote have been adopted PARIS, FRANCE, 13 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announces today that the Annual General Meeting of the Company was held on Wednesday 13 May, 2026 at the Salons de l&apos;Hôtel des Arts et Métiers, 9 bis, avenue d&apos;Iéna, 75116 Paris (France), under the chairmanship of Mr. Marc de GARIDEL, Chairman of the Board of Directors, and in the presence of the members</description>
    </item>
    <item>
      <title>Ipsen S.A. – Evolution of the composition of the Board of Directors</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-sa-evolution-of-the-composition-of-the-board-of-directors-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-sa-evolution-of-the-composition-of-the-board-of-directors-1</guid>
      <pubDate>Wed, 13 May 2026 16:15:00 GMT</pubDate>
      <description>Ipsen S.A. – Evolution of the composition of the Board of Directors PARIS, FRANCE, 13 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Mrs. Karen Witts has resigned from her position as a Director of Ipsen S.A., effective at the close of the Annual General Meeting on May 13, 2026, in order to focus on her executive responsibilities. Chair of the Audit Committee from 2022 to 2026 and member of the Compensation Committee, Mrs. Karen Witts had served as a Director of Ipsen S.A. sin</description>
    </item>
    <item>
      <title>Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-delivers-strong-sales-in-the-first-quarter-of-2026-and-confirms-its-full-year-guidance-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-delivers-strong-sales-in-the-first-quarter-of-2026-and-confirms-its-full-year-guidance-1</guid>
      <pubDate>Thu, 23 Apr 2026 05:00:00 GMT</pubDate>
      <description>Total sales growth of 22.6% at CER1 or 17.0% as reported, driven by all three therapeutic areas, with accelerating portfolio momentum outside Somatuline®, growing by 27.5% at CERStrong pipeline momentum with three Phase III readouts expected in H2 2026Confirmation of full-year 2026 guidance2 PARIS, FRANCE, 23 April 2026 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2026. Q1 2026% change€mActualCEROncology</description>
    </item>
    <item>
      <title>Ipsen S.A. - Information relating to the holding of the Combined Shareholders’ Meeting of 13 May 2026</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-sa-information-relating-to-the-holding-of-the-combined-shareholders-meeting-of-13-may-2026-2</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-sa-information-relating-to-the-holding-of-the-combined-shareholders-meeting-of-13-may-2026-2</guid>
      <pubDate>Wed, 22 Apr 2026 16:00:00 GMT</pubDate>
      <description>Information relating to the holding of the Combined Shareholders’ Meeting of 13 May 2026 of Ipsen S.A. Formalities for making available and consulting preparatory documents to the Meeting PARIS, FRANCE, 22 APRIL 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Shareholders of the Company are invited to participate in the Combined Shareholders’ Meeting of Ipsen (Euronext: IPN; ADR: IPSEY) to be held on Wednesday 13 May 2026 at 3:00 p.m. (Paris time) at the Salons de l&apos;Hôtel des A</description>
    </item>
    <item>
      <title>Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ojemdar-approved-in-the-european-union-as-the-first-targeted-therapy-in-relapsed-or-refractory-pediatric-low-grade-glioma-regardless-of-braf-alteration-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ojemdar-approved-in-the-european-union-as-the-first-targeted-therapy-in-relapsed-or-refractory-pediatric-low-grade-glioma-regardless-of-braf-alteration-1</guid>
      <pubDate>Wed, 22 Apr 2026 05:00:00 GMT</pubDate>
      <description>New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals over the past five years have focused on pediatric diseases; Ojemda® (tovorafenib) represents a rare achievement that reinforces the urgent need to close the innovation and investment gaps in pediatric therapeuticsApproval is based on pivotal Phase II FIREFLY-1 datai demonstrating meaningful and durable tumor responses PARIS, FRANCE, 22 April 2026 — Ipsen (Euronext: IPN; ADR: IPSEY) today</description>
    </item>
    <item>
      <title>Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-announces-that-beech-tree-has-obtained-an-exemption-from-the-obligation-to-submit-a-public-tender-offer-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-announces-that-beech-tree-has-obtained-an-exemption-from-the-obligation-to-submit-a-public-tender-offer-1</guid>
      <pubDate>Fri, 03 Apr 2026 05:00:00 GMT</pubDate>
      <description>PARIS, FRANCE, 3 April 2026 — Ipsen (Euronext: IPN; ADR: IPSEY) announces that Beech Tree — which directly and indirectly holds 26.03% of Ipsen S.A.’s share capital and 33.05% of its voting rights — has obtained from the French Financial Markets Authority (Autorité des marchés financiers) an exemption from the obligation to file a public tender offer for all Ipsen S.A. shares.1 This decision is part of the transfer of Mr. Henri Beaufour’s stake in Beech Tree to the Alasol Foundation. This transf</description>
    </item>
    <item>
      <title>Ipsen announces the availability of its 2025 Universal Registration Document</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-announces-the-availability-of-its-2025-universal-registration-document-4</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-announces-the-availability-of-its-2025-universal-registration-document-4</guid>
      <pubDate>Wed, 01 Apr 2026 16:00:00 GMT</pubDate>
      <description>Ipsen announces the availability of its 2025 Universal Registration Document PARIS, FRANCE, 1 APRIL 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced that its 2025 Universal Registration Document has been filed today with the French Autorité des Marchés Financiers (AMF) and registered under the number D.26-0202. The document is available on www.ipsen.com and www.amf-france.org. Copies will also be available at Ipsen’s headquarters – 70 rue Balard, 75015 Paris, France. The Universal Registration</description>
    </item>
    <item>
      <title>Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-showcases-transformative-potential-of-early-immuno-oncology-pipeline-at-aacr-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-showcases-transformative-potential-of-early-immuno-oncology-pipeline-at-aacr-1</guid>
      <pubDate>Wed, 18 Mar 2026 06:00:00 GMT</pubDate>
      <description>IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors ITGA2 revealed as novel target of Ipsen’s investigational antibody drug conjugate IPN60300, over-expressed across numerous solid tumor typesPreclinical data show potential of Ipsen’s growing collection of investigational medicines, leveraging precision immuno‑modulation to deliver differentiated anti‑tumor activity PARIS</description>
    </item>
    <item>
      <title>Ipsen - February 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-february-2026-monthly-information-relative-to-the-total-number-of-voting-rights-and-shares-composing-the-share-capital-492</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-february-2026-monthly-information-relative-to-the-total-number-of-voting-rights-and-shares-composing-the-share-capital-492</guid>
      <pubDate>Fri, 13 Mar 2026 17:00:00 GMT</pubDate>
      <description>Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights (1)28 February 2026 83,814,526 Gross total* of voting rights: 131,963,662Net total**</description>
    </item>
    <item>
      <title>Ipsen appoints Michelle C. Werner as EVP, President of North America</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-appoints-michelle-c-werner-as-evp-president-of-north-america-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-appoints-michelle-c-werner-as-evp-president-of-north-america-1</guid>
      <pubDate>Thu, 12 Mar 2026 06:30:00 GMT</pubDate>
      <description>Michelle C. Werner Photo of Michelle C. Werner, EVP, President of North America PARIS, FRANCE, 12 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Michelle C. Werner as Executive Vice President (EVP), President of North America, effective 23 March 2026. Michelle will serve on the Executive Leadership Team (ELT) and will report directly to Ipsen’s Chief Executive Officer (CEO), David Loew. “I am very pleased to welcome Michelle to Ipsen and to the Executive Leader</description>
    </item>
    <item>
      <title>Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/update-ipsen-voluntarily-withdraws-tazverikr-tazemetostat-in-follicular-lymphoma-and-epithelioid-sarcoma-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/update-ipsen-voluntarily-withdraws-tazverikr-tazemetostat-in-follicular-lymphoma-and-epithelioid-sarcoma-1</guid>
      <pubDate>Mon, 09 Mar 2026 17:37:00 GMT</pubDate>
      <description>PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision to withdraw is based on emerging data from the ongoing Phase Ib/III SYMPHONY-1 trial (evaluating tazemetostat in combination with lenalidomide plus rituximab (R2) vs R2 in follicular lymphoma). The Independent Data Monitoring Committee (IDMC) advised that, based on adverse events of secondary hemat</description>
    </item>
    <item>
      <title>Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-voluntarily-withdraws-tazverikr-tazemetostat-in-follicular-lymphoma-and-epithelioid-sarcoma-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-voluntarily-withdraws-tazverikr-tazemetostat-in-follicular-lymphoma-and-epithelioid-sarcoma-1</guid>
      <pubDate>Mon, 09 Mar 2026 06:00:00 GMT</pubDate>
      <description>PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision to withdraw is based on emerging data from the ongoing Phase Ib/III SYMPHONY-1 trial (evaluating tazemetostat in combination with lenalidomide plus rituximab (R2) vs R2 in follicular lymphoma). The Independent Data Monitoring Committee (IDMC) advised that, based on adverse events of secondary hemat</description>
    </item>
    <item>
      <title>Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-receives-positive-chmp-opinion-for-ojemdar-for-the-treatment-as-monotherapy-of-children-with-relapsed-or-refractory-braf-altered-pediatric-low-grade-glioma-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-receives-positive-chmp-opinion-for-ojemdar-for-the-treatment-as-monotherapy-of-children-with-relapsed-or-refractory-braf-altered-pediatric-low-grade-glioma-1</guid>
      <pubDate>Fri, 27 Feb 2026 11:20:00 GMT</pubDate>
      <description>If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of BRAF alterationiThe decision is based on data from the pivotal Phase II FIREFLY-1 study which demonstrated clinically meaningful and durable tumor responses with a positive impact on children’s livesii PARIS, FRANCE, 27 FEBRUARY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced to</description>
    </item>
    <item>
      <title>Quotient Sciences Extends Commercial Manufacturing Partnership for Ultra-Rare Disease Treatment</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/quotient-sciences-extends-commercial-manufacturing-partnership-for-ultra-rare-disease-treatment</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/quotient-sciences-extends-commercial-manufacturing-partnership-for-ultra-rare-disease-treatment</guid>
      <pubDate>Thu, 26 Feb 2026 14:00:00 GMT</pubDate>
      <description>Quotient Sciences, a leading integrated CRDMO (Contract Research, Development and Manufacturing Organization), is pleased to announce an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.</description>
    </item>
  </channel>
</rss>